Effects of resveratrol on gene expression in renal cell carcinoma.
Studies have shown that Resveratrol (RE) can inhibit cancer initiation, promotion, and progression. However the gene expression profile in renal cell carcinoma (RCC) in response to RE treatment has never been reported. To understand the potential anticancer effect of RE on RCC at molecular level, we profiled and analyzed the expression of 2059 cancer-related genes in a RCC cell line RCC54 treated with RE. Biological functions of 633 genes were annotated based on biological process ontology and clustered into functional categories. Twenty-nine highly differentially expressed genes in RE treated RCC54 were identified and the potential implications of some gene expression alterations in RCC carcinogenesis were identified. RE was also shown to inhibit cell growth and induce cell death of RCC cells. The expression alterations of selected genes were validated using reverse transcription polymerase chain reaction. In addition, the gene expression profiles under different RE treatments were analyzed and visualized using singular value decomposition. The findings from this study support the hypothesis that RE induces differential expression of genes that are directly or indirectly related to the inhibition of RCC cell growth and induction of RCC cell death. In addition, it is apparent that the gene expression alterations due to RE treatment depend strongly on RE concentration. This study provides a general understanding of the overall genetic response of RCC54 to RE treatment and yields insights into the understanding of the cancer preventive mechanism of RE in RCC.
Department of Cancer Biology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Ting
T
Shi
Louis S
LS
Liou
Provash
P
Sadhukhan
Zhong-Hui
ZH
Duan
Andrew C
AC
Novick
John G
JG
Hissong
Alexandru
A
Almasan
Joseph A
JA
DiDonato
D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000503:physiopathology*; D018890:Chemoprevention; D018450:Disease Progression; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000503:physiopathology*; D010636:Phenols; D000077185:Resveratrol; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D013267:Stilbenes / Q000494:pharmacology*; D014665:Vasodilator Agents
D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic; D010636:Phenols; D013267:Stilbenes; D014665:Vasodilator Agents; D012264:Ribonucleotide Reductases; D000077185:Resveratrol